What a reporter found when uncovering why federal agents allowed a deadly drug to hit the streets

Summary

An AP investigation revealed the DEA allowed fentanyl pills into New Mexico to build cases. A whistleblower claims this gambled with public safety, violating DOJ rules. Federal officials defend the tactic, stating it saves more lives by targeting larger dealers.

Key Takeaways

1. The U.S. Drug Enforcement Administration permitted hundreds of thousands of fentanyl pills to be distributed in New Mexico as part of an effort to build bigger federal prosecutions.
2. Howell told me that decision, which came as fatal overdoses hit their peak around the country, was akin to "providing one fentanyl pill to each person at a football stadium."
3. The Justice Department's Office of Professional Responsibility, a kind of internal affairs office, found in 2024 that the DEA and U.S. attorney's office had made reasonable decisions in deciding to allow drugs to go unseized and that their inaction posed no "specific danger to public health."

Statement Breakdown

• Claimed Facts: 50% of statements the article presents as facts
• Opinions: 30% of statements classified as editorial or subjective
• Claims: 20% of statements surfaced for additional reader evaluation

Credibility & Bias Reasoning

Credibility assessment: The article relies on investigative reporting, internal documents, and whistleblower accounts. While the DEA disputes some claims, the detailed sourcing and cross-referencing suggest a strong effort to verify information. The inclusion of official statements provides a balanced perspective.

Bias assessment: Investigative Skepticism. The article frames the DEA's actions through the lens of a whistleblower's concerns and critical analysis of federal drug policy. It highlights potential ethical and safety compromises, suggesting a critical stance towards law enforcement discretion.

Note: This article presents findings from an investigative report. While it includes official responses, it heavily features a whistleblower's perspective and critical analysis of federal agency actions.

Credibility flag: Investigative Reporting

Claimed Facts (7)

• This is a direct statement of the article's central investigative finding.
• This details the methodology and sources used in the investigation.
• This is a factual statement about a government designation.
• This describes the initial discovery of the whistleblower complaint.
• This explains a specific detail of how the whistleblower was identified.
• This states the procedural action taken by the whistleblower.
• This describes the initial reaction and action by the Office of Special Counsel.

Opinions (6)

• This is a subjective statement about the difficulty of obtaining information.
• This is an interpretation of the story's significance and a commentary on transparency.
• This is a generalization about the power and impact of federal agents' decisions.
• This is a critical observation about public trust in government actions.
• This implies a deliberate action by the DOJ to enable the practice despite concerns.
• This presents a critical interpretation of the internal investigation's findings.

Claims (8)

• While 'walking' drugs is a known tactic, the article presents it as a broad, long-standing DEA practice without specific evidence for all drug types.
• This is a simplified explanation for a complex issue, potentially downplaying other factors.
• While true for many fentanyl pills, this statement generalizes and might not cover all forms of fentanyl encountered.
• The claim of 'almost always' is a strong generalization; while common, it's difficult to definitively prove for every single pill.
• This is a highly emotive and metaphorical comparison, intended to shock rather than provide a precise factual account of the risk.
• While Uballez acknowledges the tactic, the framing of it 'saving more lives' is a subjective justification for a controversial practice.
• This is a denial from the DEA, which is a claim that is contested by the whistleblower and the reporting, making its truthfulness debatable within the context of the article.
• This is a defense of the DEA's actions, which is directly contradicted by the whistleblower's claims and the article's framing.

Key Sources

• Jim Mustian — Reporter, Associated Press
• Joshua Goodman — Journalist, Associated Press
• Associated Press — News Agency
• David Howell — Whistleblower, Former DEA Agent
• Del Quentin Wilber — Editor
• Alex Uballez — Former U.S. Attorney in Albuquerque
• Amanda Wozniak — Spokesperson, DEA
• U.S. Drug Enforcement Administration — Federal Law Enforcement Agency
• Justice Department — U.S. Federal Department
• Office of Special Counsel — Government Agency
• Justice Department's Office of Professional Responsibility — Internal Affairs Office